Related Experiment Video
Updated: Dec 27, 2025

Forskolin-induced Swelling in Intestinal Organoids: An In Vitro Assay for Assessing Drug Response in Cystic Fibrosis Patients
Published on: February 11, 2017
Different CFTR modulator combinations downregulate inflammation differently in cystic fibrosis
Heledd H Jarosz-Griffiths1,2, Thomas Scambler2,3, Chi H Wong2,3
1Leeds Institute of Medical Research at St James's, University of Leeds, Leeds, United Kingdom.
Cystic Fibrosis Transmembrane conductance Regulator (CFTR) modulators reduce the exaggerated inflammatory response in cystic fibrosis patients. These drugs decrease key inflammatory markers, suggesting potential clinical benefits beyond improved CFTR function.
Area of Science:
- Immunology
- Pharmacology
- Genetics
Background:
- Patients with cystic fibrosis (CF) exhibit an enhanced NLRP3-inflammasome signature, characterized by increased IL-18, IL-1β, caspase-1 activity, and ASC speck release.
- This exaggerated inflammatory response contributes to CF pathology.
Purpose of the Study:
- To investigate the anti-inflammatory effects of CFTR modulators in cystic fibrosis.
- To determine if CFTR modulators can downregulate the enhanced NLRP3-inflammasome signature observed in CF patients.
Main Methods:
- In vitro studies using CF monocytes treated with ivacaftor/lumacaftor or ivacaftor/tezacaftor.
- In vivo assessment of adults with CF receiving CFTR modulator treatments over three months.
- Measurement of serum and peripheral blood mononuclear cell (PBMC) inflammatory markers (IL-18, IL-1β, TNF, IL-10, caspase-1 activity) following stimulation.
Main Results:
- In vitro, ivacaftor/lumacaftor and ivacaftor/tezacaftor reduced IL-18 in CF monocytes. Ivacaftor/tezacaftor also reduced IL-1β.
- In adults with CF, serum IL-18 and TNF significantly decreased with both treatments. IL-1β declined only with ivacaftor/tezacaftor.
- Both CFTR modulator combinations significantly decreased IL-18, TNF, and caspase-1 activity in stimulated PBMCs, while increasing IL-10. Ivacaftor/tezacaftor alone reduced IL-1β and pro-IL-1β mRNA.
Conclusions:
- CFTR modulator combinations demonstrate potent anti-inflammatory properties by downregulating key components of the NLRP3-inflammasome pathway.
- These anti-inflammatory effects, in addition to restoring CFTR function, may contribute to improved clinical outcomes in cystic fibrosis patients.
More Related Videos
08:00Generation of Human Nasal Epithelial Cell Spheroids for Individualized Cystic Fibrosis Transmembrane Conductance Regulator Study
Published on: April 11, 2018
05:56Implementation of Non-invasive Point of Care Transient Elastography for Evaluation of Liver Disease in Pediatric Populations with Cystic Fibrosis
Published on: August 29, 2025
Related Concept Videos
Cystic Fibrosis: Management
Sinus disease and chronic...
Cystic Fibrosis: Pathogenesis
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Antiasthma Drugs: Leukotriene Modifiers
Leukotriene modifiers work through two distinct mechanisms:
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids